Status: Recruiting
Infliximab for Immune Checkpoint Inhibitor Associated AKI
This is a multi-center, 1:1 randomized pilot study examining the efficacy and safety of infliximab 5mg/kg x 1 paired with 2 weeks of prednisone 1mg/kg per day for 2 weeks versus standard-of-care glucocorticoid therapy (prednisone 1mg/kg/day x 2 weeks followed by a 4 week taper) on the rate and speed of renal recovery from immune checkpoint inhibitor-associated AKI.
Participants needed: 44
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Massachusetts General HospitalUpdated: Oct 9, 2026Locations: 3
Eligibility criteria
Age ≥18 years. [+4]
Any condition requiring high dose glucocorticoids (GCs) (>10 mg/day prednisone e... [+12]